Webdisclosure.com

Search

HAEMATO AG HAEMATO: HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe

Directive transparence : information réglementée

25/10/2021 10:25


DGAP-Media / 25.10.2021 / 10:25

HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe

Seoul and Schönefeld, 25th October 2021 - HAEMATO PHARM GmbH ("HAEMATO"), a wholly owned subsidiary of HAEMATO AG (ISIN: DE000289VV1), is expanding its own portfolio with a botulinum toxin product from the pharmaceutical company Huons Bio Pharma Co., Ltd. ("Huons BioPharma"), based in Seoul, Korea. For this purpose, Huons BioPharma and HAEMATO have concluded an exclusive licence and supply agreement. With the purchase of a botulinum toxin product under its own brand, HAEMATO is further expanding its "Lifestyle & Aesthetics" division. Due to the partnership with Huons BioPharma, HAEMATO's "time-to-market" is considerably shortened, as the otherwise lengthy in-house development of a toxin is not necessary.

The "International Society of Aesthetic Plastic Surgery" shows in its study1 published in January 2021 that the botulinum toxin treatment is the most performed non-invasive beauty treatment worldwide. Since 2015, the number of treatments with botulinum toxin products has increased by more than 35% - a trend that will continue in the future due to the increased acceptance of beauty treatments. The product will ensure the long-term supply of the parent company, M1 Kliniken AG (ISIN: DE000A0STSQ8), one of the leading providers of beauty treatments in Europe, with an attractively priced botulinum toxin product. In addition, the product is to be distributed in all European markets.

The drug, marketed under the brand names LIZTOX(R) and HUTOX(R) in Korea as well as other countries, is an injectable type A botulinum toxin. It is used for the treatment and "smoothing" of moderate to severe wrinkles in the facial area. After going through the European marketing authorization process, which includes clinical trials, HAEMATO plans to roll-out the product across Europe under its own brand. From today's perspective, issuing of the marketing authorization of the product is expected in approximately three to four years.

Patrick Brenske, CEO of HAEMATO AG, comments on the conclusion of the licence and supply agreement as follows: "We are pleased to have found in Huons BioPharma, a renowned and successful partner in the field of lifestyle & aesthetics, with whom we intend to establish a promising product in the European beauty market."

The parties have agreed not to disclose detailed financial terms of the agreement.

About HAEMATO:
HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on trading in high-priced specialty pharmaceuticals (with a therapeutic focus on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at www.haemato.de

About Huons BioPharma:
Huons BioPharma Co., Ltd. was spun off from the holding company, Huons Global Co., Ltd. in April 2021 to expand the botulinum toxin product business, enter into global market and focus on the development of new biopharmaceuticals. The company aims to improve the quality of life by developing biopharmaceuticals for intractable diseases as well as to advance the international roll-out of HUTOX(R). Huons BioPharma future objectives are the expansion of indications as well as the further development of next-generation botulinum toxin through continuous R&D investment.

About LIZTOX(R) / HUTOX(R)
LIZTOX(R) or HUTOX(R), is an injectable botulinum toxin type A indicated for the treatment and "smoothing" of moderate to severe wrinkles in the facial area, has been registered and marketed in Korea and several other Asian countries. Since its launch in Korea in the second quarter of 2020, LIZTOX(R) managed to strengthen its position among leading botulinum toxin products in Korea.

1 International Society of Aesthetic Plastic Surgery (2021): ISAPS International Survey On Aesthetic/Cosmetic Procedures




Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
ir@haemato.ag


End of Media Release


Issuer: HAEMATO AG
Key word(s): Trades

25.10.2021 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany
Phone: +49 (0)30 897 30 86 70
Fax: +49 (0)30 897 30 86 79
E-mail: ir@haemato.ag
Internet: www.haemato.ag
ISIN: DE000A289VV1
WKN: A289VV
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1243110

 
End of News DGAP Media

1243110  25.10.2021 

fncls.ssp?fn=show_t_gif&application_id=1243110&application_name=news&site_id=symex